RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kyowa Kirin Co Stock

Kyowa Kirin Co Equity 2025

Kyowa Kirin Co Equity

850.81 B JPY

Ticker

4151.T

ISIN

JP3256000005

WKN

858523

In 2025, Kyowa Kirin Co's equity was 850.81 B JPY, a 1.72% increase from the 836.42 B JPY equity in the previous year.

Kyowa Kirin Co Aktienanalyse

What does Kyowa Kirin Co do?

Kyowa Kirin Co Ltd is a Japanese pharmaceutical company that was founded over 70 years ago. The company is headquartered in Tokyo and has been listed on the stock exchange since 1974. It has over 6,000 employees worldwide and conducts research and development in the fields of bioscience and biotechnology. The history of Kyowa Kirin Co Ltd began in 1949 when the company was established as Kyowa Hakko Seiyaku Co Ltd. Initially, the company primarily focused on the production of pharmaceutical products and chemicals. In the 1990s, the company expanded globally and announced a focus on researching novel drugs. Today, Kyowa Kirin Co Ltd is a leading company in bioscience and biotechnology, offering a wide range of products and services. The company is divided into several business segments, including pharmaceuticals, biopharmaceuticals, and diagnostics. Kyowa Kirin Co Ltd has a comprehensive product range, from the asthma medication Nucala to the hearing loss medication Nouriast®. Nucala is an innovative medication for the treatment of severe asthma and was approved by the FDA in 2015. The medication has proven to be highly effective in clinical studies and has the potential to improve the lives of millions of people. Another important product from Kyowa Kirin Co Ltd is the cancer medication Mogamulizumab. The medication is used for the treatment of T-cell lymphomas, a rare form of lymph node cancer. Mogamulizumab was approved in Japan in 2012 and has since proven to be an effective medication in treating T-cell lymphomas. The company also conducts research and development in the field of regenerative medicine. An example of this is the medication Regsorin, which is used for the treatment of peripheral vascular diseases. Regsorin is a biologic made from the body's own fibronectin protein and is able to strengthen and repair blood vessels and capillaries. Another important business area for Kyowa Kirin Co Ltd is diagnostics. The company produces and distributes diagnostic tests for a range of diseases, including allergies, infectious diseases, and cancer. The diagnostics division of Kyowa Kirin Co Ltd works closely with the company's other business segments to develop and market innovative diagnostic tests. Overall, Kyowa Kirin Co Ltd is an outstanding example of a pharmaceutical company specializing in the research and development of novel drugs and therapies for serious diseases. The company has an impressive history of innovation over the decades and has established itself as a leading provider in biosciences and biotechnology. With its wide product range and innovative research efforts, Kyowa Kirin Co Ltd is a key player in the global market for medical therapies and diagnostics. Kyowa Kirin Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Kyowa Kirin Co's Equity

Kyowa Kirin Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Kyowa Kirin Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Kyowa Kirin Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Kyowa Kirin Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Kyowa Kirin Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Kyowa Kirin Co stock

What is the equity of Kyowa Kirin Co this year?

Kyowa Kirin Co has equity of 850.81 B JPY this year.

What was the equity of Kyowa Kirin Co compared to the previous year?

The equity of Kyowa Kirin Co has increased/decreased by 1.72% increased compared to the previous year.

What impact does a high equity have on investors of Kyowa Kirin Co?

A high equity is advantageous for investors of Kyowa Kirin Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Kyowa Kirin Co?

A low equity can be a risk for investors of Kyowa Kirin Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Kyowa Kirin Co affect the company?

An increase in equity of Kyowa Kirin Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Kyowa Kirin Co affect the company?

A reduction in equity of Kyowa Kirin Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Kyowa Kirin Co?

Some factors that can affect the equity of Kyowa Kirin Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Kyowa Kirin Co so important for investors?

The equity of Kyowa Kirin Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Kyowa Kirin Co take to change the equity?

To change equity, Kyowa Kirin Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Kyowa Kirin Co pay?

Over the past 12 months, Kyowa Kirin Co paid a dividend of 58 JPY . This corresponds to a dividend yield of about 2.64 %. For the coming 12 months, Kyowa Kirin Co is expected to pay a dividend of 60.05 JPY.

What is the dividend yield of Kyowa Kirin Co?

The current dividend yield of Kyowa Kirin Co is 2.64 %.

When does Kyowa Kirin Co pay dividends?

Kyowa Kirin Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.

How secure is the dividend of Kyowa Kirin Co?

Kyowa Kirin Co paid dividends every year for the past 23 years.

What is the dividend of Kyowa Kirin Co?

For the upcoming 12 months, dividends amounting to 60.05 JPY are expected. This corresponds to a dividend yield of 2.73 %.

In which sector is Kyowa Kirin Co located?

Kyowa Kirin Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kyowa Kirin Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kyowa Kirin Co from 3/1/2026 amounting to 30 JPY, you needed to have the stock in your portfolio before the ex-date on 12/29/2025.

When did Kyowa Kirin Co pay the last dividend?

The last dividend was paid out on 3/1/2026.

What was the dividend of Kyowa Kirin Co in the year 2024?

In the year 2024, Kyowa Kirin Co distributed 56 JPY as dividends.

In which currency does Kyowa Kirin Co pay out the dividend?

The dividends of Kyowa Kirin Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kyowa Kirin Co

Our stock analysis for Kyowa Kirin Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kyowa Kirin Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.